S12 Ep32: ADC-Based Combinations Gain Momentum in Bladder Cancer Management: With Chandler Park, MD; and Vadim Koshkin, MD

In this week's episode of MedNews Week's Oncology Unplugged, host Chandler Park, MD, a medical oncologist at Norton Cancer Institute in Louisville, Kentucky, sat down with Vadim Koshkin, MD, an associate professor of medicine in the Division of Hematology and Oncology in the Department of Medicine at the University of California, San Francisco (UCSF) School of Medicine, as well as a genitourinary medical oncologist at the UCSF Helen Diller Comprehensive Cancer Center.Drs Park and Koshkin discussed recent developments in bladder cancer management, including the significant benefits of enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) compared with platinum-based chemotherapy in the metastatic setting, key outcomes from the phase 3 NIAGARA trial (NCT03732677) of perioperative durvalumab (Imfinzi) plus chemotherapy in muscle-invasive bladder cancer, the potential for disitamab vedotin (RC48-ADC) to join the advanced urothelial cancer treatment paradigm, and what the future may look like for HER2-targeted therapies in this disease.